Willow Biosciences Inc.
WLLW.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,142.33% | 1,955.66% | 148.48% | 646.07% | -81.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,142.33% | 1,955.66% | 148.48% | 646.07% | -81.34% |
| Cost of Revenue | -5.89% | -303.03% | -12.56% | -37.43% | -46.82% |
| Gross Profit | 157.39% | 655.22% | 130.16% | 88.84% | 41.62% |
| SG&A Expenses | -41.57% | -33.39% | 29.36% | -38.06% | -59.92% |
| Depreciation & Amortization | -96.25% | -5.38% | -44.66% | -21.94% | -21.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.87% | -12.82% | -7.80% | -35.85% | -51.28% |
| Operating Income | 90.59% | 76.86% | 54.85% | 61.09% | 49.59% |
| Income Before Tax | 87.36% | 50.31% | 52.35% | 58.99% | 50.45% |
| Income Tax Expenses | -- | -1,274.46% | -- | 832.21% | -- |
| Earnings from Continuing Operations | 87.37% | 64.00% | 45.08% | 54.04% | 50.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.37% | 64.00% | 45.08% | 54.04% | 50.41% |
| EBIT | 90.59% | 76.86% | 54.85% | 61.09% | 49.59% |
| EBITDA | 89.89% | 88.97% | 57.18% | 63.93% | 50.71% |
| EPS Basic | 89.21% | 68.53% | 51.49% | 55.09% | 51.23% |
| Normalized Basic EPS | 89.13% | 57.14% | 58.33% | 59.70% | 48.31% |
| EPS Diluted | 89.21% | 68.53% | 51.49% | 55.09% | 51.23% |
| Normalized Diluted EPS | 89.13% | 57.14% | 58.33% | 59.70% | 48.31% |
| Average Basic Shares Outstanding | 15.47% | 14.51% | 13.60% | 2.48% | 1.39% |
| Average Diluted Shares Outstanding | 15.47% | 14.51% | 13.60% | 2.48% | 1.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |